Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
This section weighs security guarantees across Pow and Pos, helping readers decide which consensus offers stronger protections for their needs.
24,327 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
SoftBank dismisses Elon Musk’s orbital data center idea, choosing immediate Earth-based expansion. The move comes as ...
New Census Bureau data reveals a stark generational imbalance: aging baby boomers dominate assets while younger Ameri...
Looking to turn a $1,000 into lasting passive income? This guide shows how dividend stocks yielding over 8.5% can fit...
FuelCell Energy leads a broader rally in the fuel-cell sector as Russell index inclusion fuels passive inflows. Bloom...
Palantir chief executive officer Alex Karp charges that frontier AI models are siphoning value from enterprises. The ...
The Fed kept its policy rate unchanged, setting the stage for a slow drift in HYSA yields. Savers await any signal fr...
Many investors hoped the Trumpflation era was fading. This in-depth guide explains why wall street thinks trumpflatio...
SpaceX leaps past the $2 trillion mark as it eyes a spot in the Nasdaq-100, triggering intense debate about the susta...
Retail investors flock to a $50-priced ETF that looks like a safe cash substitute as rate expectations shift. Here’s ...
Robinhood’s Layer-2 push and the launch of perpetual futures on a crypto DEX could shift how retail traders access cr...
When a top executive sells a large block, investors want to know what it really signals. This analysis breaks down th...